BAM
NYMX

Belpointe Asset Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Belpointe Asset Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,221
Closed -$755 – 3674
2023
Q1 		$755 Buy
+2,221
New +$903 ﹤0.01% 3525

Other funds holding NYMX

CF
Corrigan Financial Middletown, Rhode Island $485M AUM 4.29% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Belpointe Asset Management's NYMX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2023, closing a stake of 2,221 shares — an estimated $755 sold.

Belpointe Asset Management first reported a position in NYMX in Q1 2023 and held it in 1 quarter. The position peaked at $755 in Q1 2023. 36 funds tracked by Wall St. Rank hold NYMX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Nymox Pharmaceutical Corp position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,221 Nymox Pharmaceutical Corp shares in Q2 2023, an estimated $755.
  • Belpointe Asset Management first reported a position in Nymox Pharmaceutical Corp in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Nymox Pharmaceutical Corp position peaked at $755 in Q1 2023.
  • 36 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.